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Abstract 
Background: Delirium is a frequently occurring syndrome in patients admitted to the intensive care unit (ICU) or 
medium care unit (MCU), yet the pathophysiology remains poorly understood. An excess of central serotonin can 
lead to an altered mental status, associated with autonomic hyperactivity, and neuromuscular excitation. Drugs 
with serotonergic properties are frequently and for prolonged periods administered to ICU/MCU patients. Therefore, 
central serotonergic toxicity may constitute a predisposing, contributing or precipitating factor in the emergence of 
delirium. The purpose of the present study is to determine the number of patients admitted to the ICU or MCU who 
are diagnosed with delirium and who show characteristics of serotonin toxicity in association with the administration 
of serotonergic drugs.
Methods: During a 10-week prospective observational cohort study in the ICU and MCU, patients aged 18 or older, 
diagnosed with delirium in the ICU or MCU, were included. Patients were considered as delirious in case of a posi-
tive CAM-ICU and/or at the start of haloperidol prescription on suspicion of delirium. Once included, patients were 
screened for recent administered serotonergic drugs and screened for physical signs associated with serotonin toxic-
ity by a standardized physical examination by a specifically trained physician.
Results: A total of 61 patients diagnosed with delirium were enrolled. In 44 out of 61 patients (72 %), the use of drugs 
potentially contributing to serotonergic toxicity was recorded. Out of 44 patients, seven (16 %) patients showed physi-
cal signs of serotonin toxicity and in addition met the Hunter serotonin toxicity criteria, suggesting the presence of 
serotonergic toxicity. None of these patients were recognized as such by the treating physicians.
Conclusions: A significant proportion of delirious patients in the ICU might in fact be classified as suffering from 
central serotonin toxicity. The awareness of potential serotonin toxicity is low among physicians.
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Background
‘Altered mental status’ is a frequently occurring symptom 
in patients admitted to the intensive care unit (ICU) or 
medium care unit (MCU). Most of these altered men-
tal states are clinically diagnosed as delirium. Delirium, 
mostly symptomatically treated with haloperidol, is con-
sidered to result from transient organic cerebral dysfunc-
tion and presents as an acute neuropsychiatric syndrome 
characterized by a disturbance in attention and cognition 
that tends to fluctuate during the course of the day. The 
reported incidence of delirium in the ICU varies between 
16 and 89  % [1]. Although it is clear that delirium has 
a multifactorial nature, the pathophysiology remains 
poorly understood. Regardless of the cause, delirium 
is a severe syndrome and associated with many nega-
tive outcomes such as longer ICU and hospital admis-
sion, increased mortality, decreased long-term cognitive 
function and in addition in elderly patients with demen-
tia increased rates of cognitive decline and admission to 
institutions [2–4]. In this respect, the length of duration 
of delirium seems to be an important prognostic factor: 
A longer duration of delirium is associated with worse 
global cognition and executive function [5].
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Several mechanisms are thought to contribute to delir-
ium, such as inflammation, metabolic derangements, 
electrolyte disorders, stress response and genetic factors, 
medication, along with imbalance of neurotransmitters 
[3, 6]. Regarding neurotransmitters, most research has 
been done on the importance of reduced acetylcholine 
and excess dopamine in the pathogenesis of delirium. 
However, an excess of the serotonergic neurotransmis-
sion, as seen in the context of an intentional overdose 
with serotonergic drugs, can also produce an altered 
mental state such as delirium, suggesting a role of seroto-
nin (5-hydroxytryptamine or 5-HT) in the pathophysiol-
ogy of delirium [6].
Nonetheless, little to no research has been conducted 
on this subject.
Drugs with serotonergic properties have the ability to 
increase the level of serotonin or to act as direct agonists 
of postsynaptic serotonin receptors in the central nerv-
ous system (CNS) and therefore the ability to create sero-
tonergic toxicity. Due to the vulnerable state of critically 
ill patients and altered pharmacokinetics with changes 
in distribution volumes, protein binding and changes 
in blood brain barrier, serotonergic drugs might have a 
greater effect on serotonergic neurotransmission than we 
are aware of, consequently leading to toxicity more eas-
ily. To date, several drugs are known to have serotonergic 
properties. Most commonly known serotonergic drugs 
are antidepressants, such as serotonin reuptake inhibi-
tors (SRIs) and tricyclic antidepressants (TCAs), though 
these drugs are not very often prescribed to patients in 
the ICU or MCU. An excess of CNS 5-HT, known as ser-
otonin syndrome or serotonin/serotonergic toxicity, can 
lead to an altered mental status (e.g., restlessness, agita-
tion, delirium), autonomic hyperactivity and instability 
(e.g., tachycardia, fluctuating blood pressure, diaphoresis, 
diarrhea) and neuromuscular excitation (e.g., hyperre-
flexia, myoclonus, rigidity). Serotonergic toxicity (ST) in 
itself is generally associated with a favorable prognosis. 
Most cases report an overdose of one or more seroton-
ergic drugs, but toxicity can also result from therapeutic 
drug use or inadvertent interactions between drugs [7].
Treatment mainly requires discontinuation of sero-
tonergic drugs and supportive care. However, most 
physicians are not aware of drugs that do seem to have 
serotonergic properties but are not evidently marked so. 
Yet some of them, to the contrary, are being frequently 
used in the ICU and MCU. Opioid analgesics (e.g., fen-
tanyl and tramadol) and anti-emetics (e.g., ondansetron-
like drugs and metoclopramide) are examples of such 
drugs. In addition, methylene blue and the antibiotic lin-
ezolid, which are used occasionally, are associated with 
inducing serotonin toxicity [7, 8]. Despite the fact that 
some of these drugs with serotonergic properties are 
frequently administered for a longer period of time to 
patients in the ICU and MCU, most physicians currently 
do not consider serotonergic toxicity as a possible cause 
of delirium. Since delirium in ICU and MCU patients is 
most often very persistent and therapy resistant, gaining 
understanding of the pathophysiology of delirium is evi-
dently of utmost importance for creating better patient 
outcomes. We therefore set up an observational prospec-
tive cohort study to determine whether delirious patients 
admitted to the ICU and MCU show characteristics that 
possibly match serotonergic toxicity, in order to gain 
more clarity on whether or not serotonergic toxicity 
should be considered as one of the contributing factors in 
delirious patients.
Methods
This study was approved by the local medical ethical 
committee of VU Medical Centre of Amsterdam, which 
waived the need for informed consent since no interven-
tions were carried out and only non-traceable data were 
collected.
Study design and study population
We performed a prospective observational cohort study 
during a period of 10  weeks at the ICU and MCU for 
adults of VU University medical center in Amsterdam. 
Patients aged 18  years or older, with a positive Confu-
sion Assessment Measurement for the ICU (CAM-ICU), 
were included in the study. CAM-ICU is the most widely 
used validated instrument to detect delirium in critical ill 
patients, both mechanically and not mechanically venti-
lated patients [9, 10]. Furthermore, patients who received 
haloperidol on prescription of physicians on the indica-
tion of presumed delirium were considered to be deliri-
ous and were subsequently included, even in case of a 
negative CAM-ICU. Haloperidol is only prescribed by 
physicians in our department in case of suspected delir-
ium. Patients could only be included once to minimize 
selection bias. Patients who had a prolonged admission 
and who were diagnosed with delirium previously before 
the start of the study, as well as patients diagnosed with 
delirium before admission to the ICU or MCU, were 
excluded.
Once included, demographic characteristics, such as 
age, gender, and severity of illness expressed in Acute 
Physiology and Chronic Health Evaluation (APACHE) II 
and IV score, were collected as routinely present in the 
patient data management system (Metavision®).
To determine the presence of serotonergic drugs, all 
medical charts were reviewed. We checked specifically 
for all drugs, which were associated with serotonin toxic-
ity according to Boyer et al. [7] given at the day of diag-
nosing delirium as well as the previous week. Of these 
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drugs, fentanyl is the standard first choice in our depart-
ment for analgesia. Additionally, we checked whether 
drugs that would inhibit cytochrome P450 3A4 iso-
enzyme (CYP 3A4) and 2D6 iso-enzyme (CYP 2D6) were 
administered, since fentanyl and other serotonergic and 
dopaminergic drugs are extensively metabolized by these 
iso-enzymes. In addition, we registered other co-medica-
tion such as sedatives that would alter mental status.
To determine whether included patients showed physi-
cal signs associated with serotonin toxicity, a separate 
standardized physical examination focusing on serotonin 
toxicity was performed by a specifically trained physi-
cian. We included those physical signs that were associ-
ated with serotonin toxicity according to Sternbach and 
Dunkley et al. [11, 12] along with vital signs such as heart 
rate and blood pressure. We defined tachycardia as a 
heart rate >90 beats per minute, hypertension as blood 
pressure >140/90 mmHg and fever as a central body tem-
perature >38 °C. Furthermore, we reported whether there 
was fluctuation in blood pressure (>35  mmHg systolic) 
or heart rate (>40  beats/min). We relied on the Hunter 
serotonin toxicity criteria for the definition of serotonin 
toxicity: Meeting the Hunter criteria meant that there 
was suspicion of serotonin toxicity. Physicians were not 
informed of our findings, since it would intervene with 
our follow-up. Patients were followed up 1  week after 
the diagnosis of delirium was made to determine the 
whereabouts of the patients, the current mental status 
according to discharge letters or standard delirium scor-
ing tools and whether haloperidol was still being admin-
istered. Furthermore, we checked whether serotonergic 
drugs were administered the week following diagnosing 
delirium.
We applied descriptive statistics to present the data.
Results
During the 10-week study period, a total of 442 patients 
were admitted to the ICU and MCU, of whom 76 were 
diagnosed with delirium, either by a positive CAM-ICU, 
by start of haloperidol on suspicion of delirium in case of 
a negative CAM-ICU or by both. A total of 15 patients 
were excluded, leaving 61 (Fig. 1). Once included, physi-
cal examination was performed within 48 h, with a mean 
of 21 h (SD 15,5 h). The characteristics of the total study 
population are depicted in Table  1. The cohort had a 
mean age of 65 and a high severity of illness. On average, 
the diagnosis delirium was made at day 5 (standard devia-
tion, SD 4). Of all included delirious patients (n = 61), six 
had a history of alcohol abuse, three were admitted with 
acute alcohol intoxication and two had taken ampheta-
mines before admission to the ICU. In 36 out of 61 (59 %) 
patients, the Richmond Agitation and Sedation Scale 
(RASS) was above 0 at the point of diagnosing delirium, 
which meant they were agitated.
In 44 out of 61 delirious patients (72  %), the use of 
drugs potentially contributing to serotonin toxicity was 
recorded at the start of the study, meaning serotoner-
gic drugs were being administered either at the point of 
diagnosing delirium and/or the previous week. The drugs 
associated with serotonin toxicity used in the ICU and 
MCU are depicted in Table  2. Only those medications 
that were being administered during ICU admission 
are depicted. None of the other medication associated 
with serotonin toxicity according to Boyer et  al. was 
administered.
Suspected serotonin toxicity
In seven (16 %) out of the 44 patients, who were delirious 
and had received serotonergic drugs, there were physi-
cal signs, i.e., neurological and autonomic symptoms, 
strongly suggesting serotonin toxicity. All seven had a 
positive CAM-ICU and two were receiving haloperidol 
as treatment of delirium. These seven patients were all 
given serotonergic drugs both at point of the diagnosis 
delirium and the whole previous week and consequently 
met the Hunter serotonin toxicity criteria. All seven 
patients were admitted to the ICU. Two were admitted 
after a cardiac arrest, one was admitted after high-energy 
trauma, one was admitted after cardiothoracic surgery, 
and three were admitted for internal medicine reasons. 
Three of the seven patients had an infection or were sep-
tic when admitted, and were treated as such, but all three 
were hemodynamic and respiratory stable at enrollment. 
One patient had a psychiatric disorder, yet did not take 
serotonergic psychotropics before admission, and had a 
history of alcohol abuse, i.e., binge drinking, but none of 
the seven patients was admitted with acute drug or alco-
hol intoxication. None of the patients with suspected 
serotonin toxicity had liver failure. One patient had acute 
kidney failure. In five out of seven patients, the RASS was 
Fig. 1 Flowchart patient inclusion
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above 0, in the range from agitated to combative, and 
six out seven patients received benzodiazepines, pre-
dominantly midazolam intravenously as treatment for 
agitation.
Table  3 shows the physical characteristics comparing 
the group with suspected serotonin toxicity (n  =  7) to 
the group in which serotonin toxicity was not suspected 
(n = 54).
As can be seen, all seven patients with suspected 
serotonin toxicity had an inducible clonus. One of 
them was admitted with traumatic brain injury, yet 
none of the other delirious patients admitted to the 
ICU because of neurological (trauma) reasons showed 
an inducible clonus. In all other six patients with sus-
pected serotonin toxicity, neurological causes of clonus 
Table 1 Characteristics of study population
ICU intensive care unit, MCU medium care unit, APACHE Acute Physiology and 
Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, CAM-ICU 
Confusion Assessment Measurement for the ICU, SD standard deviation, RASS 
Richmond Agitation Sedation Scale >0 = agitated
a At point of physical examination
b At enrollment
c More than three units/day for more than 3 months
d Amphetamines
Variable N = 61
Age in years [mean (SD)] 65 (16)
Male [n (%)] 43 (71 %)
ICU admission [n (%)] 51 (84 %)
MCU admission [n (%)] 10 (16 %)
Day of admission delirium was diagnosed [mean (SD)] 5 (4)
Admission category
 Cardiac arrest [n (%)] 8 (13 %)
 Neurology/neurosurgery [n (%)] 10 (16 %)
 Multi-trauma [n (%)] 3 (5 %)
Confirmed infection [n (%)] 16 (26 %)
Acute kidney failure [n (%)] 17 (28 %)
APACHE II score [mean (SD)] 22,6 (6,8)
APACHE IV score [mean (SD)] 39 (26,2)
SOFA score [mean (SD)] 6,7 (3,2)
Comorbidity
 Psychiatric disorder [n (%)] 4 (7 %)
 Dementia [n (%)] 2 (3 %)
Mechanical ventilated [n (%)a] 25 (41 %)
Richmond Agitation and Sedation Scaleb
 Agitation (RASS > 0) [n (%)] 36 (59 %)
 Lightly sedated (RASS ≤ 0 ≥ −2) [n (%)] 23 (38 %)
 Moderate–heavily sedated (RASS < −2) [n (%)] 2 (3 %)
Sedationb [n (%)] 40 (66 %)
 Midazolam [n (%)] 13 (21 %)
 Propofol [n (%)] 13 (21 %)
 Clonidine [n (%)] 18 (30 %)
 Benzodiazepines per os [n (%)] 27 (44 %)
Chronic alcohol (ab)use [n (%)]c 6 (10 %)
Acute alcohol intoxication [n (%)] 3 (5 %)
Chronic benzodiazepine use [n (%)] 8 (13 %)
Recreational drug intoxication [n (%)]d 2 (3 %)
Morphine-like analgesics [n (%)] 20 (33 %)
Serotonergic medication [n (%)] 44 (72 %)
Table 2 Drugs associated with  serotonin toxicity used 
in the ICU/MCU
ICU intensive care unit, MCU medium care unit, n number, CYP 3A4 inhibitor 







CYP 3A4 inhibitor concomitantly (n) 16
CYP 2D6 inhibitor concomitantly (n) 24
Table 3 (Physical) characteristics
ST serotonin toxicity, SD standard deviation, n number, GMV Glasgow Coma 





Age [mean (SD)] 62 (22) 65 (16)
Admission category
 Neurology/neurosurgery (n) 0 10
 Multi-trauma (n) 1 2
Comorbidity
 Acute kidney failure (n) 1 16
 Confirmed infection (n) 3 13
 GCS [mean (SD)] 10 (4) 11 (4)
Neurological symptoms (n) 7 9
 Especially lower extremities (n) 6 2
 Inducible clonus (n) 7 1
 Hyperreflexia (n) 3 5
 Bilateral Babinski (n) 2 6
Autonomic symptoms (n) 7 35
 Hypertension (>140/90 mmHg) 3 12
 Fluctuating blood pressure 
(>35 mmHg systolic)
6 20
 Vasopressin/inotropic 0 10
 Tachycardia (>100 beats/min) 2 14
 Sinus rhythm 7 43
 Fluctuating heart rate (>40 beats/
min)
1 5
 Diaphoresis 3 4
 Hyperthermia (>38 °C) 2 7
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were excluded. In three out of seven patients, hyperre-
flexia was also present. In all patients but one (who was 
admitted with respiratory insufficiency because of a 
pneumonia and who showed besides an inducible ankle 
clonus also an inducible wrist clonus), these neurologi-
cal symptoms (i.e., clonus and/or hyperreflexia) were 
more present at the lower extremities, a characteristic 
of serotonin toxicity. Concomitantly all seven patients 
had fluctuating blood pressure, without simultaneous 
administration of vasopressor or inotropic drugs. Fur-
thermore, four out of seven patients showed diapho-
resis and/or hyperthermia in the absence of an active 
sepsis or infection.
No suspected serotonin toxicity
Out of the 54 delirious patients with no suspicion of sero-
tonin toxicity (n = 54), only one patient had an inducible 
clonus, without having received any serotonergic medi-
cation. This patient was admitted because of reduced 
consciousness of unknown origin and was suspected of 
a still delirium. There was no agitation and the inducible 
clonus was equally present at both arms and legs, which 
is not a characteristic of serotonin toxicity.
Hyperreflexia was present in five patients of out 54. 
In only two of these patients, these symptoms were 
more present in the lower extremities. Diaphoresis and 
hyperthermia were only seen in four out of 54 and seven 
out of 54 patients, respectively, some of which were 
observed during infection. Furthermore, fluctuating 
blood pressure was less common (20 out of 54), and half 
of these patients were still supported by vasopressin or 
inotropic.
Serotonergic medication prescribed at the ICU/MCU
Table  4 depicts the amount of serotonergic drugs used 
during ICU/MCU admission per group. All patients with 
suspected serotonin toxicity received intravenous fen-
tanyl continuously. Four out of seven patients received 
two or more serotonergic drugs simultaneously; two 
received fentanyl combined with metoclopramide, one 
received fentanyl, metoclopramide and ondansetron, 
and one received fentanyl combined with tramadol. 
Out of the seven patients, four also received a CYP 3A4 
inhibitor while receiving fentanyl, and in three cases 
both CYP3A4 and CYP2D6 inhibitors were administered 
concomitantly.
In the group with no suspicion of serotonin toxicity, 
most patients received no (28 %) or only one (56 %) sero-
tonergic drug. Only five patients received two or more 
drugs concomitantly, of whom three received fentanyl 
combined with ondansetron, one fentanyl with ondan-
setron and tramadol and one fentanyl combined with 
metoclopramide.
Twelve out of 29 received a CYP3A4 inhibitor while 
receiving fentanyl, 21 received CYP2D6 inhibitors, but 
only eight patients received CYP3A4 and 2D6 inhibi-
tors concomitantly while receiving serotonergic drugs. 
2D6 inhibitors were predominantly haloperidol, and in 
some cases, amiodarone, verapamil or diltiazem was 
administered.
Follow‑up
A week after initial enrollment, the patients with sus-
pected serotonin toxicity were followed up. Out of seven 
patients, four were still admitted to the ICU or MCU, of 
whom three were still delirious while having received ser-
otonergic drugs and one was not delirious anymore and 
had not received any serotonergic drugs the week after 
enrollment. The remaining three patients had been dis-
charged to the ward, of whom one patient was still deliri-
ous while having received serotonergic drugs and two 
were not delirious despite having received serotonergic 
drugs.
Discussion
This is to our best knowledge the first observational 
prospective cohort study to determine whether deliri-
ous critically ill patients who are given drugs with sero-
tonergic properties show physical signs suggesting 
central serotonergic toxicity. Since a few serotonergic 
drugs are frequently and often for a longer period of time 
administered, we hypothesize that some of these deliri-
ous patients have serotonin toxicity without physicians 
Table 4 Serotonergic drug use
ST serotonin toxicity, n number, SD standard deviation, CYP 3A4 inhibitor 






Number of serotonergic drugs  
concomitantly (n)
 None 0 17
 One 3 32
 Two or more 4 5
Fentanyl intravenously (n) 7 29
 Number of days continuous [mean 
(SD)]
6,9 (4,7) 5,6 (4,3)
 Cumulative dosage (mg) [mean (SD)] 18,5 (29,3) 14,2 (16,7)
Metoclopramide (n) 3 4
Tramadol (n) 1 1
Ondansetron (n) 1 6
CYP 3A4 inhibitor concomitantly (n) 4 12
CYP 2D6 inhibitor concomitantly (n) 3 21
 Both CYP 3A4 and 2D6 inhibitors (n) 3 8
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suspecting this. In our relatively small sample, 16 % of the 
delirious patients who were given drugs with serotoner-
gic properties demonstrated physical signs of serotonin 
toxicity and met the Hunter serotonin toxicity criteria 
compatible with serotonergic toxicity. Of all neurological 
symptoms, an inducible clonus, with or without hyper-
reflexia, and especially in the lower extremities, seems to 
be most important indication that serotonergic toxicity 
may be present, along with fluctuating blood pressure in 
the absence of vasopressor or inotropic medication. Even 
though half of the patients were still delirious after 1 week 
and serotonergic drugs were still administered, no physi-
cian suspected serotonin toxicity as a possible cause. This 
may suggest that physicians are not sufficiently aware of 
the serotonergic effects of some frequently used drugs in 
the ICU. Nor do they apparently expect serotonin toxic-
ity to occur in patients who are not on antidepressants.
We used the CAM-ICU as an instrument for detecting 
delirium. Although it is the most widely used instrument 
in critically ill patients, it can lead to false positives in 
case of heavily sedated patients, i.e., RASS-2 or 3. A study 
of Heangi et  al. [13, 14] showed that excluding patients 
with RASS-2 and 3 leads to a reduction in positives 
CAM-ICU of 22 %. In our cohort, the CAM-ICU assess-
ment has only been performed in case of a RASS of -2 of 
higher, i.e., when a patient is lightly sedated, thus expect-
ing few false positives.
Very little research has been done on serotonergic tox-
icity in the ICU. Pedavally et al. [15] performed a retro-
spective analysis of the clinical presentation of patients 
with serotonin toxicity in the ICU.
They included patients who were already diagnosed 
with serotonin toxicity before admission to the ICU, as 
well as patients who developed serotonin toxicity after 
admission. Most patients, who developed serotonergic 
toxicity during ICU admission, were on antidepressant 
therapy and developed symptoms indicative of seroton-
ergic toxicity after administering additional serotonergic 
drugs in the ICU. Patients in our cohort did not receive 
antidepressants, but drugs with less serotonergic potency.
Fentanyl is a synthetic piperidine opioid with seroton-
ergic properties. Systemic injection causes efflux of 5-HT 
in the dorsal raphe nucleus, either through direct 5-HT1A 
postsynaptic stimulation or through indirect mu-opioid 
stimulation, which causes 5-HT reuptake inhibition [16–
18]. The cytochrome P450 iso-enzyme family, especially 
CYP3A4, is responsible for the elimination of fentanyl. 
Concomitantly subscribing fluconazole or voriconazole, 
both CYP3A4 inhibitors, has shown to decrease the elim-
ination of fentanyl significantly [19]. In addition, human 
cytochrome P450 genes are highly polymorphic, leading 
to inter-individual differences in drug metabolism [20].
Metoclopramide, though it is primarily a dopamine 
antagonist, also seems to have moderate–low affinity 
to 5-HT2A, 5-HT3 and 5-HT4 receptors [21]. Combined 
with fentanyl, it might enhance the risk of inducing sero-
tonergic toxicity.
Although tramadol is not an analgesic frequently pre-
scribed in the ICU, a recent case series by Ibister et  al. 
[22] suggested that tramadol does not seem to provoke 
serotonin toxicity clinically and a study by Barann et al. 
[23] showed a concentration-dependent decrease in 
5-HT reuptake, leading to an increase in serotonin.
Since this study contained a small cohort, no definite 
conclusions can be drawn on differences in drug use 
between the two groups. It is of note that the large major-
ity of all our patients receive fentanyl at some stage. All 
patients with suspicion of serotonin toxicity had received 
fentanyl, started after admission to the ICU, and half of 
the patients had received two or more serotonergic drugs 
combined, mostly with metoclopramide. Yet no differ-
ences in the amount of days or total received dosage of 
fentanyl between the groups were present. However, 
four out of seven patients received a CYP3A4 inhibitor 
while receiving fentanyl, leading possibly to higher dos-
ages. In addition, three out of four received besides a 
CYP3A4 inhibitor also a CYP2D6 inhibitor. Metoclopra-
mide depends on CYP2D6 for inactivation. Combining 
CYP2D6 inhibitors (like haloperidol) with metoclopra-
mide could therefore potentially be an extra risk factor 
for developing serotonergic toxicity, because of its mod-
erate–low affinity to some postsynaptic 5HT receptors, 
when a patient has already been given other serotonergic 
drugs.
Some patients showed no signs of serotonin toxicity, 
despite having received multiple serotonergic agents. 
The most frequent combination of drugs in this group 
was fentanyl combined with ondansetron. Ondansetron 
is a 5-HT3 receptor antagonist. Turkel et al. [24] hypoth-
esize that by blocking the 5-HT3 subtype receptor and 
simultaneously increasing the level of serotonin through 
serotonergic drugs, the excessive serotonin selectively 
agonizes the other serotonin subtypes, such as 5-HT1A 
and 5-HT2A. However, for a relevant toxicity, 5-HT 
levels need to be increased 40-fold over baseline [25]. 
Ondansetron-like drugs might, thus, not play such a big 
role in provoking serotonergic toxicity. Another possible 
explanation, for why some patients develop serotoner-
gic toxicity and others do not, might be a combination 
of factors, such as unmeasured differences in severity of 
illness, different intra-individual susceptibility to develop 
serotonergic toxicity in terms of central serotonergic 
neurotransmission, blood–brain barrier disturbances or 
cytochrome P450 polymorphisms.
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Serotonin toxicity is not an easy diagnosis to make. 
Little research has been conducted, and most is known 
through case reports. No gold standard diagnostic test 
exists, and serotonergic toxicity is essentially a phenom-
enological diagnosis. Dunkley et  al. [12] defined the 
Hunter serotonergic toxicity criteria, which compared to 
a diagnosis made by clinical toxicologist have a sensitivity 
and specificity of 84 and 97 %, respectively. Although the 
Hunter criteria have not been developed for ICU patients 
and their specificity in the ICU has not been tested, we 
relied on the Hunter serotonin toxicity criteria.
We acknowledge that ICU patients are a difficult popu-
lation to study. Many exhibit autonomic symptoms due 
to the critically ill condition they are in, and especially 
critically ill patients might have various reasons for 
being delirious. We have to emphasize, however, that our 
patients were diagnosed with delirium at the moment 
when they were stabilized in terms of hemodynamics 
and respiratory failure and sedation was minimal. Yet all 
seven patients showed autonomic instability and hyper-
activity without active infection, support of inotropic or 
vasopressors, or drug/alcohol intoxication. Furthermore, 
the patients showed neurological symptoms that other-
wise rarely occur in patients. Relying on the Hunter crite-
ria makes misclassification unlikely.
Clinically serotonin toxicity might be difficult to dis-
tinguish from malignant neuroleptic syndrome (MNS). 
Excessive dopaminergic blockage can lead to MNS, char-
acterized by fever, muscular rigidity with elevated serum 
CK, altered mental status and autonomic dysfunction. 
It is a rare idiosyncratic drug reaction to (therapeutic) 
doses of neuroleptic agents, and although it could in the-
ory develop anytime, symptoms usually develop within 
the first 2 weeks after starting a neuroleptic agent. Sero-
tonin toxicity, to the contrary, is a spectrum of symptoms 
and a toxic reaction due to an excess of serotonin in the 
CNS, and develops quickly after administering a seroton-
ergic drug [26].
MNS is characterized by generalized lead pipe rigidity 
and bradykinesie and normal reflexia, whereas serotonin 
toxicity is characterized by neuromuscular hyperactiv-
ity (e.g., clonus, hyperreflexia) and predominantly in the 
lower extremities.
It is unlikely that the patients with suspected seroto-
nin toxicity, in our cohort, were suffering from MNS. 
Haloperidol was administered to only two out of seven 
patients, metoclopramide to only four patients and 
both for a relatively short period of time. Haloperidol 
was one of the inclusion criteria and physical examina-
tion followed within a maximum of 48  h. Furthermore, 
all seven patients showed neuromuscular hyperactivity, 
a characteristic of serotonin toxicity and no significant 
elevation of serum CK. Physical symptoms started after 
administration of serotonergic agents, and delirium was 
diagnosed on average on day five of admission.
Further studies might involve a bigger cohort, possibly 
in comparison with non-delirious patients, to determine 
risk factors in terms of drug use and precipitating and 
predisposing factors for developing serotonin toxicity. 
Furthermore, it would be of use to know whether the 
administration of a 5-HT antagonist, such as cyprohep-
tadine, in patients with suspicion of serotonin toxicity, 
would benefit in terms of symptoms that subside. Fur-
thermore, most importantly future studies should aim to 
investigate whether treatment of serotonin toxicity leads 
to earlier recovery and better patient outcome.
In summary, we have demonstrated that a significant 
proportion of patients in the ICU who have been diag-
nosed with delirium might in fact be classified as suf-
fering from serotonin toxicity. We furthermore showed 
that awareness of potential serotonin toxicity is low 
among physicians in our tertiary university ICU. How-
ever, lack of existing studies strongly suggests that this 
is not unique for our ICU. We urge for further studies 
on the incidence and prevalence of serotonin toxicity in 
ICU patients and the effect of possible early therapeutic 
interventions.
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